source
- Activist Kaos Capital pushes governance overhaul at Capricor ahead of FDA Duchenne decisionActivist investor Kaos Capital has sent a letter to Capricor Therapeutics shareholders demanding a “governance reset.” The firm asks for a meeting to nominate two independent directors, create an M…
- FDA rejects Osteal Therapeutics' combo therapy for joint-implant infectionsThe U.S. Food and Drug Administration rejected Osteal Therapeutics' lead combination therapy late last month. The agency cited concerns that prevented approval of the product intended to treat infe…